威高骨科(688161) - 2024 Q4 - 年度业绩预告

Financial Performance - The company expects a net profit attributable to shareholders for 2024 to be between 200 million and 240 million CNY, an increase of 87.685 million to 127.685 million CNY compared to the previous year, representing a year-on-year growth of 78.07% to 113.68%[3] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between 191 million and 231 million CNY, an increase of 83.1024 million to 123.1024 million CNY compared to the previous year, indicating a year-on-year increase of 77.02% to 114.09%[3] - The previous year's net profit attributable to shareholders was 112.315 million CNY, and the net profit after deducting non-recurring gains and losses was 107.8976 million CNY[4] - As of the announcement date, no significant uncertainties affecting the accuracy of the performance forecast have been identified[9] Business Strategy - The company is actively implementing volume-based procurement policies and adjusting its business strategy to optimize cost control and enhance cooperation with medical institutions, aiming to maximize market share and customer coverage[7] - The company is focusing on refined performance management and optimizing marketing structures to effectively reduce sales expense ratios[7] Product Development - New product lines in artificial bones, sports medicine, and minimally invasive spine surgery are developing rapidly, laying a solid foundation for new business layouts[7] - The company plans to increase R&D investment in key products and expand its orthopedic innovation product matrix through independent research and external acquisitions in 2025[8] International Expansion - The company aims to enhance its international brand influence and market share by accelerating overseas business expansion and targeting strategic markets[8] - The company has initiated comprehensive overseas product registration and is promoting its products through market academic promotion[7]